Sign up USA
Proactive Investors - Run By Investors For Investors

Spine Injury Solutions boosted by new certificates

Medtech group Spine Injury Solutions (OTC:SPIN) added 2.38% to US$0.43 as it got key certifications for its Quad Video HALO System.
Spine Injury Solutions boosted by new certificates
The firm provides services for patients who have sustained spine injuries resulting from traumatic accidents

Medtech group Spine Injury Solutions  (OTC:SPIN) added 2.38% to US$0.43 as it got key certifications for its Quad Video HALO System.

The device is a medical real-time video and documentation accessory and it means it has now completed requirements for sales and marketing of medical applications under both US and EU standards.

Dr William Donovan, chief of Spine Injury Solutions, said: "The QVH has undergone rigorous internal testing and has been used to great success in conjunction with SPIN's medical affiliates in a diagnostic program for treating more than a thousand spine injury cases.

"The QVH not only provides protection for the medical provider, through secure video transparency and real-time documentation of the procedures, but also gives great comfort to the patient knowing his or her medical provider will 'do his best' in performing the procedure."

He added: "Two years ago we realized the potential of the QVH. And, that with modifications, it could be expanded dramatically outside our own needs, not only for use with the tens of thousands of fluoroscopes (both fixed and portable) currently in service, but also in operating rooms world-wide."

The firm says it's now been in discussions with various groups about sales, leasing and marketing of the QVH both in the USA and Europe with focus on teaching hospitals, pain management groups, factoring companies, who deal with personal injury A/R cases, ER/ urgent care centers and hospitals. 

Giles_55af4ddca6481.jpg


Register here to be notified of future SPIN Company articles
View full SPIN profile View Profile

Related Articles

shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use